Clinical Trial Update: Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) [Phase 3]

View source ↗

Summary

Phase 3 study comparing a JAK inhibitor INC424 (ruxolitinib) to best available care in hydroxyurea-resistant or -intolerant polycythemia vera; results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycythemia Vera

Drugs mentioned

• INC424 (nilotinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Polycythemia Vera | Phase 3 | Status: COMPLETED | Results posted: 2015-03-06